Porcine circovirus type 2 (PCV2) evolution before and after the vaccination introduction: A large scale epidemiological study

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Franzo, Giovanni ^a   Tucciarone, Claudia Maria ^a   Cecchinato, Mattia ^a   Drigo, Michele ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

SINGLE STRANDED DNA; VIRUS VACCINE;

ANIMAL; BIOLOGY; CIRCOVIRIDAE INFECTION; CIRCOVIRUS; CODON; GENETICS; GENOTYPE; IMMUNOLOGY; MUTATION; OPEN READING FRAME; PIG; PREVALENCE; PROTEIN QUATERNARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; SWINE DISEASE; VACCINATION; VIROLOGY; VIRUS CAPSID;

ANIMALS; CAPSID; CIRCOVIRIDAE INFECTIONS; CIRCOVIRUS; CODON; COMPUTATIONAL BIOLOGY; DNA, SINGLE-STRANDED; GENOTYPE; MUTATION; OPEN READING FRAMES; PREVALENCE; PROTEIN STRUCTURE, QUATERNARY; PROTEIN STRUCTURE, TERTIARY; SUS SCROFA; SWINE; SWINE DISEASES; VACCINATION; VIRAL VACCINES;

EID: 85006771067     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep39458     Document Type: Article

References (63)

1. Fabisiak, M., Szczotka, A., Podgórska, K. & Stadejek, T. Prevalence of infection and genetic diversity of porcine circovirus type 2 (PCV2) in wild boar (Sus scrofa) in Poland. J. Wildl. Dis. 48, 612-618 (2012).
2. Segalés, J. et al. The natural history of porcine circovirus type 2: from an inoffensive virus to a devastating swine disease? Vet. Microbiol. 165, 13-20 (2013).
3. Lv, Q. Z., Guo, K. K. & Zhang, Y. M. Current understanding of genomic DNA of porcine circovirus type 2. Virus Genes 49, 1-10 (2014).
4. Segales, J., Allan, G. M. & Domingo, M. Porcine circovirus diseases. Anim. Health Res. Rev. 6, 119-142 (2005).
5. Segalés, J. & Segales, J. Porcine circovirus type 2 (PCV2) infections: Clinical signs, pathology and laboratory diagnosis. Virus Res. 164, 10-19 (2012).
6. Beach, N. M. & Meng, X.-J. Efficacy and future prospects of commercially available and experimental vaccines against porcine circovirus type 2 (PCV2). Virus Res. 164, 33-42 (2012).
7. Rose, N., Opriessnig, T., Grasland, B. & Jestin, A. Epidemiology and transmission of porcine circovirus type 2 (PCV2). Virus Res. 164, 78 (2012).
8. Gao, Z. et al. Identification and characterization of two novel transcription units of porcine circovirus 2. Virus Genes 47, 268-275 (2013).
9. Lv, Q., Guo, K., Xu, H., Wang, T. & Zhang, Y. Identification of Putative ORF5 Protein of Porcine Circovirus Type 2 and Functional Analysis of GFP-Fused ORF5 Protein. PLoS One 10, e0127859 (2015).
10. Cheung, A. K. Porcine circovirus: Transcription and DNA replication. Virus Res. 164, 46 (2012).
11. Khayat, R. et al. The 2.3-Angstrom structure of porcine circovirus 2. J. Virol. 85, 7856-7862 (2011).
12. Nawagitgul, P. et al. Open reading frame 2 of porcine circovirus type 2 encodes a major capsid protein. J. Gen. Virol. 81, 2281 (2000).
13. Franzo, G., Cortey, M., Segalés, J., Hughes, J. & Drigo, M. Phylodynamic analysis of porcine circovirus type 2 reveals global waves of emerging genotypes and the circulation of recombinant forms. Mol. Phylogenet. Evol. 100 (2016).
14. Vidigal, P. M. P. et al. Tripping over emerging pathogens around the world: A phylogeographical approach for determining the epidemiology of Porcine circovirus-2 (PCV-2), considering global trading. Virus Res. 163, 320-327 (2012).
15. Franzo, G. et al. Revisiting the taxonomical classification of Porcine Circovirus type 2 (PCV2): Still a real challenge. Virol. J. 12, (2015).
16. Olvera, A., Cortey, M., Segalés, J. & Segales, J. Molecular evolution of porcine circovirus type 2 genomes: phylogeny and clonality. Virology 357, 175-185 (2007).
17. Carman, S. et al. The emergence of a new strain of porcine circovirus-2 in Ontario and Quebec swine and its association with severe porcine circovirus associated disease-2004-2006. Can. J. Vet. Res. 72, 259-268 (2008).
18. Constans, M., Ssemadaali, M., Kolyvushko, O. & Ramamoorthy, S. Antigenic Determinants of Possible Vaccine Escape by Porcine Circovirus Subtype 2b Viruses. Bioinform. Biol. Insights 9, 1 (2015).
19. Guo, L. J., Lu, Y. H., Wei, Y. W., Huang, L. P. & Liu, C. M. Porcine circovirus type 2 (PCV2): genetic variation and newly emerging genotypes in China. Virol. J. 7, 273 (2010).
20. Xiao, C. T., Halbur, P. G. & Opriessnig, T. Global molecular genetic analysis of porcine circovirus type 2 (PCV2) sequences confirms the presence of four main PCV2 genotypes and reveals a rapid increase of PCV2d. J. Gen. Virol., doi: vir.0.000100 [pii] (2015).
21. Firth, C., Charleston, M. A., Duffy, S., Shapiro, B. & Holmes, E. C. Insights into the evolutionary history of an emerging livestock pathogen: porcine circovirus 2. J. Virol. 83, 12813-12821 (2009).
22. Shen, H. G., Halbur, P. G. & Opriessnig, T. Prevalence and phylogenetic analysis of the current porcine circovirus 2 genotypes after implementation of widespread vaccination programmes in the USA. J. Gen. Virol., doi: 10.1099/vir.0.039552-0 (2012).
23. Chae, C. Commercial porcine circovirus type 2 vaccines: Efficacy and clinical application. Vet. J. 194, 151 (2012).
24. Segalés, J. Best practice and future challenges for vaccination against porcine circovirus type 2. Expert Rev. Vaccines 14, 473-487 (2015).
25. Seo, H. W. et al. Genetic and antigenic characterization of a newly emerging porcine circovirus type 2b mutant first isolated in cases of vaccine failure in Korea. Arch. Virol. 159, 3107-3111 (2014).
26. Xiao, C.-T. T., Halbur, P. G. & Opriessnig, T. Complete genome sequence of a novel porcine circovirus type 2b variant present in cases of vaccine failures in the United States. J. Virol. 86, 12412-12469 (2012).
27. Opriessnig, T., Gerber, P. F., Xiao, C.-T., Mogler, M. & Halbur, P. G. A commercial vaccine based on PCV2a and an experimental vaccine based on a variant mPCV2b are both effective in protecting pigs against challenge with a 2013 US variant mPCV2b strain. Vaccine 32, 230-237 (2014).
28. Opriessnig, T. et al. Commercial PCV2a-based vaccines are effective in protecting naturally PCV2b-infected finisher pigs against experimental challenge with a 2012 mutant PCV2. Vaccine 32, 4342-4348 (2014).
29. FitzSimons, D. et al. Long-Term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine 23, 4158-4166 (2005).
30. Cecchinato, M. et al. Avian metapneumovirus (AMPV) attachment protein involvement in probable virus evolution concurrent with mass live vaccine introduction. Vet. Microbiol. 146, 24-34 (2010).
31. Read, A. F. & Mackinnon, M. J. Pathogen evolution in a vaccinated world. Evol. Heal. Dis. 2, 139-152 (2008).
32. Ssemadaali, M. A., Ilha, M. & Ramamoorthy, S. Genetic diversity of porcine circovirus type 2 and implications for detection and control. Res. Vet. Sci. 103, 179-186 (2015).
33. Kekarainen, T., Gonzalez, A., Llorens, A. & Segalés, J. Genetic variability of porcine circovirus 2 in vaccinating and non-vaccinating commercial farms. J. Gen. Virol. 95, 1734-1742 (2014).
34. Franzo, G. et al. International trades, local spread and viral evolution: The case of porcine circovirus type 2 (PCV2) strains heterogeneity in Italy. Infect. Genet. Evol. 32 (2015).
35. Ruiz-Fons, F., Segales, J. & Gortazar, C. A review of viral diseases of the European wild boar: effects of population dynamics and reservoir role. Vet. J. 176, 158-169 (2008).
36. Vicente, J. et al. Epidemiological study on porcine circovirus type 2 (PCV2) infection in the European wild boar (Sus scrofa). Vet. Res. 35, 243-253 (2004).
37. Toplak, I. et al. Study of the genetic variability of porcine circovirus type 2 detected in Serbia and Slovenia. Acta Vet. Hung. 60, 409-420 (2012).
38. Turcitu, M. A. et al. Genetic diversity of porcine circovirus type 2 (PCV2) in the Romanian wild boar population. Res. Vet. Sci. 91, e103-e106 (2011).
39. Williams, P. D. Darwinian interventions: Taming pathogens through evolutionary ecology. Trends Parasitol. 26, 83-92 (2010).
40. Read, A. F. et al. Imperfect vaccination can enhance the transmission of highly virulent pathogens. PLoS Biol 13, e1002198 (2015).
41. Opriessnig, T., Xiao, C.-T. T., Gerber, P. F. & Halbur, P. G. Emergence of a novel mutant PCV2b variant associated with clinical PCVAD in two vaccinated pig farms in the US concurrently infected with PPV2. Vet. Microbiol. 163, 177-183 (2013).
42. Guo, L. et al. A porcine circovirus type 2 (PCV2) mutant with 234 amino acids in capsid protein showed more virulence in vivo, compared with classical PCV2a/b strain. PLoS One 7, e41463 (2012).
43. Reiner, G., Hofmeister, R. & Willems, H. Genetic variability of porcine circovirus 2 (PCV2) field isolates from vaccinated and nonvaccinated pig herds in Germany. Vet. Microbiol. 180, 41-48 (2015).
44. Mahe, D. et al. Differential recognition of ORF2 protein from type 1 and type 2 porcine circoviruses and identification of immunorelevant epitopes. J. Gen. Virol. 81, 1815-1824 (2000).
45. Shang, S.-B. et al. Fine mapping of antigenic epitopes on capsid proteins of porcine circovirus, and antigenic phenotype of porcine circovirus type 2. Mol. Immunol. 46, 327-334 (2009).
46. Trible, B. R. et al. Antibody recognition of porcine circovirus type 2 capsid protein epitopes after vaccination, infection, and disease. Clin. Vaccine Immunol. 18, 749-757 (2011).
47. Lekcharoensuk, P. et al. Epitope mapping of the major capsid protein of type 2 porcine circovirus (PCV2) by using chimeric PCV1 and PCV2. J. Virol. 78, 8135-8145 (2004).
48. Saha, D. et al. Antigenic subtyping and epitopes competition analysis of porcine circovirus type 2 using monoclonal antibodies. Vet. Microbiol. 157, 13-22 (2012).
49. Martin, D. P., Murrell, B., Golden, M., Khoosal, A. & Muhire, B. RDP4: Detection and analysis of recombination patterns in virus genomes . Virus Evol. 1(1), doi: 10.1093/ve/vev003 (2015).
50. Burch, D. Porcine circovirus vaccines-where are we? Pig Prog. 24, 7-9 (2008).
51. Katoh, K. & Standley, D. M. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol. Biol. Evol. 30, 772-780 (2013).
52. Abascal, F., Zardoya, R. & Telford, M. J. TranslatorX: Multiple alignment of nucleotide sequences guided by amino acid translations. Nucleic Acids Res. 38, W7-W13 (2010).
53. Drummond, A. J., Suchard, M. A., Xie, D. & Rambaut, A. Bayesian phylogenetics with BEAUti and the BEAST 1.7. Mol. Biol. Evol. 29, 1969 (2012).
54. Darriba, D., Taboada, G. L., Doallo, R. & Posada, D. JModel Test 2: More models, new heuristics and parallel computing. Nat. Methods 9, 772 (2012).
55. Baele, G. F. A. U. et al. Improving the accuracy of demographic and molecular clock model comparison while accommodating phylogenetic uncertainty. Molecular biology and evolution JID 8501455, doi: 10.1093/molbev/mss084 (2012).
56. Murrell, B. et al. Detecting individual sites subject to episodic diversifying selection. PLoS Genet. 8, e1002764 (2012).
57. Murrell, B. et al. FUBAR: A fast, unconstrained bayesian approximation for inferring selection. Mol. Biol. Evol. 30, 1196-1205 (2013).
58. Kosakovsky Pond, S. L. & Frost, S. D. W. Not so different after all: A comparison of methods for detecting amino acid sites under selection. Mol. Biol. Evol. 22, 1208-1222 (2005).
59. Lemey, P. The phylogenetic handbook: A practical approach to phylogenetic analysis and hypothesis testing (Cambridge University Press, 2009).
60. Pond, S. L. K. HyPhy: hypothesis testing using phylogenies. Bioinformatics 21, 676 (2005).
61. Murrell, B. et al. Modeling HIV-1 drug resistance as episodic directional selection. PLoS Comput. Biol. 8, e1002507 (2012).
62. Price, M. N., Dehal, P. S. & Arkin, A. P. FastTree 2-Approximately maximum-likelihood trees for large alignments. PLoS One 5, e9490 (2010).
63. Ge, M. Epitope screening of the PCV2 Cap protein by use of a random peptide-displayed library and polyclonal antibody. Virus Res. 177, 103-107 (2013).